| Catalog | Description | Size | Price (USD) | Qty |
|---|---|---|---|---|
| GBM-4302-50MG | Disopyramide | 50mg | $74.00 | |
| GBM-4302-250MG | Disopyramide | 250mg | $200.00 |
| Bioassays Specification | |
| Bio-Activity | Sodium channel blocker |
| Chemical Name | 4-(Diisopropylamino)-2-phenyl-2-(2-pyridyl)butyramide |
| Function / Pharmacology | Clinically useful sodium channel blocker used as an antiarrhythmic for treatment of ventricular tachycardia1 and hypertrophic cardiomyopathy2. It decreases the rate of diastolic depolarization, decreases the upstroke velocity and increases the action potential duration of normal cardiac cells. It decreases the disparity between infarcted and normal myocardium refractory periods. Disopyramide has no effect on α or β-adrenergic receptors but does display significant anticholinergic effects.3 |
| CAS# | 3737-09-5 |
| MW | 339.5 |
| Molecular Formula | C21H29N3O |
| Solubility | Soluble in DMSO (up to at least 25 mg/ml) or in ethanol (up to at least 35 mg/ml). |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Heel et al. (1978), Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias; Drugs 15 331 2) Verlinden et al. (2015), Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug; Pharmacotherapy 35 1164 3) Nakajima et al. (1989), Anti-Cholinergic Effects of Quinidine, Disopyramide, and Procainamide in Isolated Atrial Myocytes: Mediation by Different Molecular Mechanisms; Circ. Res. 64 297 |
| Protein Specification | |
| Purity | >98% |
| Bioassays Specification | |
| Bio-Activity | Sodium channel blocker |
| Chemical Name | 4-(Diisopropylamino)-2-phenyl-2-(2-pyridyl)butyramide |
| Function / Pharmacology | Clinically useful sodium channel blocker used as an antiarrhythmic for treatment of ventricular tachycardia1 and hypertrophic cardiomyopathy2. It decreases the rate of diastolic depolarization, decreases the upstroke velocity and increases the action potential duration of normal cardiac cells. It decreases the disparity between infarcted and normal myocardium refractory periods. Disopyramide has no effect on α or β-adrenergic receptors but does display significant anticholinergic effects.3 |
| CAS# | 3737-09-5 |
| MW | 339.5 |
| Molecular Formula | C21H29N3O |
| Solubility | Soluble in DMSO (up to at least 25 mg/ml) or in ethanol (up to at least 35 mg/ml). |
| Supplied | powder |
| Storage as supplied | -20°C |
| Ship temp | Ambient |
| References | 1) Heel et al. (1978), Disopyramide: a review of its pharmacological properties and therapeutic use in treating cardiac arrhythmias; Drugs 15 331 2) Verlinden et al. (2015), Disopyramide for Hypertrophic Cardiomyopathy: A Pragmatic Reappraisal of an Old Drug; Pharmacotherapy 35 1164 3) Nakajima et al. (1989), Anti-Cholinergic Effects of Quinidine, Disopyramide, and Procainamide in Isolated Atrial Myocytes: Mediation by Different Molecular Mechanisms; Circ. Res. 64 297 |
| Protein Specification | |
| Purity | >98% |
